Clearing the Air in Severe Asthma ManagementImproving Patient Outcomes Through Shared Clinical Decision Making
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127.
Castro M, et al. N Engl J Med. 2018;378(26):2486-2496.
Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma.
Busse WW, et al. Adv Ther. 2018;35(5):737-748.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, et al. Lancet Respir Med. 2015;3(5):355-366.
Corren J, et al. N Engl J Med. 2017;377(10):936-946.
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
D’Amato G, et al. Ther Clin Risk Manag. 2007;3(4):613-619.
Denlinger LC, et al. Am J Respir Crit Care Med. 2017;195(3):302-313.
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S, et al. Lancet Respir Med. 2016;4(9):699-707.
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM, et al. Lancet. 2016;388(10056):2128-2141.
Israel E, Reddel HK. N Engl J Med. 2017;377(10):965-976.
Kartush AG, et al. Am J Rhinol Allergy. 2018:1945892418814768.
Kim MA, et al. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.
Medrek SK, et al. Curr Allergy Asthma Rep. 2017;17(10):69.
Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207.
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG, et al. Lancet Respir Med. 2016;4(7):549-556.
Passalacqua G, et al. Asthma Res Pract. 2015;1:6.
Asthma yardstick: practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.
Chipps BE, et al. Ann Allergy Asthma Immunol. 2017;118:133-142.
Porsbjerg C, Menzies-Gow, A. Respirology. 2017;22(4):651-661.
Rabe KF, et al. N Engl J Med. 2018;378(26):2475-2485.
Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.
Bachert C, et al. JAMA. 2016;315(5):469-749.
Clearing the Air in Severe Asthma Management - Part 1
John J. Oppenheimer, MD
Clearing the Air in Severe Asthma Management - Part 2
John J. Oppenheimer, MD
Improving Patient Outcomes Through Shared Clinical Decision Making
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Improving Outcomes for Patients with COPD
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A New Era in Precision Medicine
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
From Guideline Recommendations to Daily Clinical Decision-Making
Interdisciplinary Management of Patients With Severe Asthma
Optimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis